The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice

Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and translational science 2016-08, Vol.9 (4), p.201-206
Hauptverfasser: Luo, J, Imai, H, Ohyama, T, Hashimoto, S, Hasunuma, T, Inoue, Y, Kotegawa, T, Ohashi, K, Uemura, N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 206
container_issue 4
container_start_page 201
container_title Clinical and translational science
container_volume 9
creator Luo, J
Imai, H
Ohyama, T
Hashimoto, S
Hasunuma, T
Inoue, Y
Kotegawa, T
Ohashi, K
Uemura, N
description Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUCAJ/AUCwater is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUCAJ 150mL/AUCwater, AUCAJ 300mL/AUCwater, and AUCAJ 600mL/AUCwater were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful.
doi_str_mv 10.1111/cts.12400
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5351340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1815705910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5460-ed041ea67c842f2c728c6ccccd9df9097c761c766bde7b6f2254419051466de53</originalsourceid><addsrcrecordid>eNqNkt9qFDEUxgdRbK1e-AIS8EYvtk0y-TNzIyxr1yqFSrvqZcgmZ7pZM8k4mbHdO99An9EnMbp10YLggZAD58fHdw5fUTwm-JDkOjJDOiSUYXyn2CeS00mFBb276znbKx6ktMZYlKLi94s9KkkthaD7xdfFCtDble5bbeJHF2BwBh1fdzGNPaAhojlcxwaCtnmGXELvox9b-P7l20voIFgIg9-gc7CjAYtcQCeg_bDaoItxuYZsDM2j9_HKhUt01muPprZ1waWh14OLAX1wwwpNu84DejM6Aw-Le432CR7d_AfFu_nxYnYyOT179Xo2PZ0YzgSegMWMgBbSVIw21EhaGWFy2do2Na6lkYLkJ5YW5FI0lHLGSI05YUJY4OVB8WKr243LFqzJe2R3qutdq_uNitqpvyfBrdRl_Kx4yUnJcBZ4diPQx08jpEG1LhnwXgeIY1KkIlxiXpP_QgnN3qTM6NNb6DqOfciXUJRWteCMszJTz7eU6WNKPTQ73wSrn4lQ-fDqVyIy--TPRXfk7whk4GgLXDkPm38rqdniYiv5A1_hwyE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289654543</pqid></control><display><type>article</type><title>The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Luo, J ; Imai, H ; Ohyama, T ; Hashimoto, S ; Hasunuma, T ; Inoue, Y ; Kotegawa, T ; Ohashi, K ; Uemura, N</creator><creatorcontrib>Luo, J ; Imai, H ; Ohyama, T ; Hashimoto, S ; Hasunuma, T ; Inoue, Y ; Kotegawa, T ; Ohashi, K ; Uemura, N</creatorcontrib><description>Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUCAJ/AUCwater is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUCAJ 150mL/AUCwater, AUCAJ 300mL/AUCwater, and AUCAJ 600mL/AUCwater were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful.</description><identifier>ISSN: 1752-8054</identifier><identifier>EISSN: 1752-8062</identifier><identifier>DOI: 10.1111/cts.12400</identifier><identifier>PMID: 27197662</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Administration, Oral ; Beverages ; Blood &amp; organ donations ; Clinical trials ; Drug dosages ; Exposure ; Female ; Fexofenadine ; Fruit juices ; Healthy Volunteers ; Humans ; Laboratories ; Male ; Malus ; Medical research ; Oral administration ; Pharmaceuticals ; Pharmacokinetics ; Studies ; Terfenadine - administration &amp; dosage ; Terfenadine - analogs &amp; derivatives ; Terfenadine - blood ; Terfenadine - pharmacokinetics</subject><ispartof>Clinical and translational science, 2016-08, Vol.9 (4), p.201-206</ispartof><rights>2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics</rights><rights>2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5460-ed041ea67c842f2c728c6ccccd9df9097c761c766bde7b6f2254419051466de53</citedby><cites>FETCH-LOGICAL-c5460-ed041ea67c842f2c728c6ccccd9df9097c761c766bde7b6f2254419051466de53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351340/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351340/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27197662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luo, J</creatorcontrib><creatorcontrib>Imai, H</creatorcontrib><creatorcontrib>Ohyama, T</creatorcontrib><creatorcontrib>Hashimoto, S</creatorcontrib><creatorcontrib>Hasunuma, T</creatorcontrib><creatorcontrib>Inoue, Y</creatorcontrib><creatorcontrib>Kotegawa, T</creatorcontrib><creatorcontrib>Ohashi, K</creatorcontrib><creatorcontrib>Uemura, N</creatorcontrib><title>The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice</title><title>Clinical and translational science</title><addtitle>Clin Transl Sci</addtitle><description>Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUCAJ/AUCwater is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUCAJ 150mL/AUCwater, AUCAJ 300mL/AUCwater, and AUCAJ 600mL/AUCwater were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful.</description><subject>Administration, Oral</subject><subject>Beverages</subject><subject>Blood &amp; organ donations</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Exposure</subject><subject>Female</subject><subject>Fexofenadine</subject><subject>Fruit juices</subject><subject>Healthy Volunteers</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Male</subject><subject>Malus</subject><subject>Medical research</subject><subject>Oral administration</subject><subject>Pharmaceuticals</subject><subject>Pharmacokinetics</subject><subject>Studies</subject><subject>Terfenadine - administration &amp; dosage</subject><subject>Terfenadine - analogs &amp; derivatives</subject><subject>Terfenadine - blood</subject><subject>Terfenadine - pharmacokinetics</subject><issn>1752-8054</issn><issn>1752-8062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkt9qFDEUxgdRbK1e-AIS8EYvtk0y-TNzIyxr1yqFSrvqZcgmZ7pZM8k4mbHdO99An9EnMbp10YLggZAD58fHdw5fUTwm-JDkOjJDOiSUYXyn2CeS00mFBb276znbKx6ktMZYlKLi94s9KkkthaD7xdfFCtDble5bbeJHF2BwBh1fdzGNPaAhojlcxwaCtnmGXELvox9b-P7l20voIFgIg9-gc7CjAYtcQCeg_bDaoItxuYZsDM2j9_HKhUt01muPprZ1waWh14OLAX1wwwpNu84DejM6Aw-Le432CR7d_AfFu_nxYnYyOT179Xo2PZ0YzgSegMWMgBbSVIw21EhaGWFy2do2Na6lkYLkJ5YW5FI0lHLGSI05YUJY4OVB8WKr243LFqzJe2R3qutdq_uNitqpvyfBrdRl_Kx4yUnJcBZ4diPQx08jpEG1LhnwXgeIY1KkIlxiXpP_QgnN3qTM6NNb6DqOfciXUJRWteCMszJTz7eU6WNKPTQ73wSrn4lQ-fDqVyIy--TPRXfk7whk4GgLXDkPm38rqdniYiv5A1_hwyE</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Luo, J</creator><creator>Imai, H</creator><creator>Ohyama, T</creator><creator>Hashimoto, S</creator><creator>Hasunuma, T</creator><creator>Inoue, Y</creator><creator>Kotegawa, T</creator><creator>Ohashi, K</creator><creator>Uemura, N</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>7QO</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>201608</creationdate><title>The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice</title><author>Luo, J ; Imai, H ; Ohyama, T ; Hashimoto, S ; Hasunuma, T ; Inoue, Y ; Kotegawa, T ; Ohashi, K ; Uemura, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5460-ed041ea67c842f2c728c6ccccd9df9097c761c766bde7b6f2254419051466de53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Administration, Oral</topic><topic>Beverages</topic><topic>Blood &amp; organ donations</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Exposure</topic><topic>Female</topic><topic>Fexofenadine</topic><topic>Fruit juices</topic><topic>Healthy Volunteers</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Male</topic><topic>Malus</topic><topic>Medical research</topic><topic>Oral administration</topic><topic>Pharmaceuticals</topic><topic>Pharmacokinetics</topic><topic>Studies</topic><topic>Terfenadine - administration &amp; dosage</topic><topic>Terfenadine - analogs &amp; derivatives</topic><topic>Terfenadine - blood</topic><topic>Terfenadine - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luo, J</creatorcontrib><creatorcontrib>Imai, H</creatorcontrib><creatorcontrib>Ohyama, T</creatorcontrib><creatorcontrib>Hashimoto, S</creatorcontrib><creatorcontrib>Hasunuma, T</creatorcontrib><creatorcontrib>Inoue, Y</creatorcontrib><creatorcontrib>Kotegawa, T</creatorcontrib><creatorcontrib>Ohashi, K</creatorcontrib><creatorcontrib>Uemura, N</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, J</au><au>Imai, H</au><au>Ohyama, T</au><au>Hashimoto, S</au><au>Hasunuma, T</au><au>Inoue, Y</au><au>Kotegawa, T</au><au>Ohashi, K</au><au>Uemura, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice</atitle><jtitle>Clinical and translational science</jtitle><addtitle>Clin Transl Sci</addtitle><date>2016-08</date><risdate>2016</risdate><volume>9</volume><issue>4</issue><spage>201</spage><epage>206</epage><pages>201-206</pages><issn>1752-8054</issn><eissn>1752-8062</eissn><abstract>Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUCAJ/AUCwater is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUCAJ 150mL/AUCwater, AUCAJ 300mL/AUCwater, and AUCAJ 600mL/AUCwater were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>27197662</pmid><doi>10.1111/cts.12400</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1752-8054
ispartof Clinical and translational science, 2016-08, Vol.9 (4), p.201-206
issn 1752-8054
1752-8062
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5351340
source MEDLINE; DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central
subjects Administration, Oral
Beverages
Blood & organ donations
Clinical trials
Drug dosages
Exposure
Female
Fexofenadine
Fruit juices
Healthy Volunteers
Humans
Laboratories
Male
Malus
Medical research
Oral administration
Pharmaceuticals
Pharmacokinetics
Studies
Terfenadine - administration & dosage
Terfenadine - analogs & derivatives
Terfenadine - blood
Terfenadine - pharmacokinetics
title The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A42%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Pharmacokinetic%20Exposure%20to%20Fexofenadine%20is%20Volume%E2%80%90Dependently%20Reduced%20in%20Healthy%20Subjects%20Following%20Oral%20Administration%20With%20Apple%20Juice&rft.jtitle=Clinical%20and%20translational%20science&rft.au=Luo,%20J&rft.date=2016-08&rft.volume=9&rft.issue=4&rft.spage=201&rft.epage=206&rft.pages=201-206&rft.issn=1752-8054&rft.eissn=1752-8062&rft_id=info:doi/10.1111/cts.12400&rft_dat=%3Cproquest_pubme%3E1815705910%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289654543&rft_id=info:pmid/27197662&rfr_iscdi=true